nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—UGT1A4—Tamoxifen—breast cancer	0.11	0.245	CbGbCtD
Asenapine—CYP2D6—breast cancer	0.109	0.538	CbGaD
Asenapine—CYP3A4—breast cancer	0.0936	0.462	CbGaD
Asenapine—HTR6—Raloxifene—breast cancer	0.0589	0.131	CbGbCtD
Asenapine—HTR2B—Raloxifene—breast cancer	0.0526	0.117	CbGbCtD
Asenapine—CYP1A2—Anastrozole—breast cancer	0.0246	0.055	CbGbCtD
Asenapine—CYP1A2—Toremifene—breast cancer	0.0225	0.0503	CbGbCtD
Asenapine—CYP3A4—Exemestane—breast cancer	0.017	0.038	CbGbCtD
Asenapine—CYP2D6—Idarubicin—breast cancer	0.0154	0.0343	CbGbCtD
Asenapine—CYP3A4—Letrozole—breast cancer	0.0145	0.0323	CbGbCtD
Asenapine—CYP3A4—Anastrozole—breast cancer	0.0129	0.0288	CbGbCtD
Asenapine—CYP3A4—Toremifene—breast cancer	0.0118	0.0263	CbGbCtD
Asenapine—CYP3A4—Fulvestrant—breast cancer	0.011	0.0245	CbGbCtD
Asenapine—CYP3A4—Thiotepa—breast cancer	0.00979	0.0218	CbGbCtD
Asenapine—CYP3A4—Ixabepilone—breast cancer	0.00895	0.02	CbGbCtD
Asenapine—CYP3A4—Lapatinib—breast cancer	0.00862	0.0192	CbGbCtD
Asenapine—CYP1A2—Tamoxifen—breast cancer	0.00823	0.0184	CbGbCtD
Asenapine—CYP2D6—Vinorelbine—breast cancer	0.00752	0.0168	CbGbCtD
Asenapine—CYP2D6—Tamoxifen—breast cancer	0.00678	0.0151	CbGbCtD
Asenapine—CYP3A4—Raloxifene—breast cancer	0.00653	0.0146	CbGbCtD
Asenapine—CYP1A2—Fluorouracil—breast cancer	0.00607	0.0135	CbGbCtD
Asenapine—CYP3A4—Vinorelbine—breast cancer	0.00478	0.0107	CbGbCtD
Asenapine—CYP2D6—Vinblastine—breast cancer	0.00463	0.0103	CbGbCtD
Asenapine—CYP3A4—Tamoxifen—breast cancer	0.00431	0.00962	CbGbCtD
Asenapine—CYP3A4—Mitoxantrone—breast cancer	0.00421	0.00938	CbGbCtD
Asenapine—CYP3A4—Paclitaxel—breast cancer	0.00336	0.00749	CbGbCtD
Asenapine—CYP3A4—Irinotecan—breast cancer	0.00331	0.00739	CbGbCtD
Asenapine—CYP3A4—Vinblastine—breast cancer	0.00295	0.00657	CbGbCtD
Asenapine—CYP2D6—Doxorubicin—breast cancer	0.00285	0.00635	CbGbCtD
Asenapine—CYP3A4—Docetaxel—breast cancer	0.00243	0.00541	CbGbCtD
Asenapine—CYP3A4—Doxorubicin—breast cancer	0.00181	0.00403	CbGbCtD
Asenapine—UGT1A4—endocrine gland—breast cancer	0.0006	0.0348	CbGeAlD
Asenapine—HRH2—skin of body—breast cancer	0.00057	0.033	CbGeAlD
Asenapine—HTR1E—female gonad—breast cancer	0.000564	0.0327	CbGeAlD
Asenapine—HRH2—adrenal gland—breast cancer	0.000434	0.0251	CbGeAlD
Asenapine—ADRA2C—nipple—breast cancer	0.000416	0.0241	CbGeAlD
Asenapine—HRH2—endocrine gland—breast cancer	0.000376	0.0218	CbGeAlD
Asenapine—CYP1A2—nipple—breast cancer	0.000361	0.0209	CbGeAlD
Asenapine—HTR2B—skin of body—breast cancer	0.000338	0.0196	CbGeAlD
Asenapine—HRH1—nipple—breast cancer	0.000338	0.0196	CbGeAlD
Asenapine—ADRA2A—nipple—breast cancer	0.000332	0.0192	CbGeAlD
Asenapine—HTR2B—endometrium—breast cancer	0.000319	0.0185	CbGeAlD
Asenapine—HTR7—epithelium—breast cancer	0.000304	0.0176	CbGeAlD
Asenapine—ADRB1—adipose tissue—breast cancer	0.0003	0.0174	CbGeAlD
Asenapine—HTR2B—uterus—breast cancer	0.000294	0.017	CbGeAlD
Asenapine—ADRA1A—epithelium—breast cancer	0.000294	0.017	CbGeAlD
Asenapine—HTR1B—female reproductive system—breast cancer	0.000293	0.017	CbGeAlD
Asenapine—HTR2B—adipose tissue—breast cancer	0.000287	0.0166	CbGeAlD
Asenapine—HTR1D—female reproductive system—breast cancer	0.000284	0.0164	CbGeAlD
Asenapine—HTR2C—female reproductive system—breast cancer	0.000281	0.0163	CbGeAlD
Asenapine—ADRB1—female reproductive system—breast cancer	0.000276	0.016	CbGeAlD
Asenapine—SLC6A4—female reproductive system—breast cancer	0.000267	0.0154	CbGeAlD
Asenapine—HTR2B—female reproductive system—breast cancer	0.000264	0.0153	CbGeAlD
Asenapine—HRH2—lymph node—breast cancer	0.00026	0.0151	CbGeAlD
Asenapine—HTR2B—adrenal gland—breast cancer	0.000258	0.0149	CbGeAlD
Asenapine—ADRA2C—endometrium—breast cancer	0.000251	0.0145	CbGeAlD
Asenapine—HTR1B—endocrine gland—breast cancer	0.000248	0.0144	CbGeAlD
Asenapine—ADRA1A—adipose tissue—breast cancer	0.000237	0.0137	CbGeAlD
Asenapine—DRD2—pituitary gland—breast cancer	0.000234	0.0135	CbGeAlD
Asenapine—ADRB1—endocrine gland—breast cancer	0.000233	0.0135	CbGeAlD
Asenapine—HTR2A—embryo—breast cancer	0.000233	0.0135	CbGeAlD
Asenapine—ADRA2C—uterus—breast cancer	0.000231	0.0134	CbGeAlD
Asenapine—HTR1A—adrenal gland—breast cancer	0.000231	0.0134	CbGeAlD
Asenapine—HRH1—epithelium—breast cancer	0.000227	0.0132	CbGeAlD
Asenapine—ADRA2C—pituitary gland—breast cancer	0.000227	0.0132	CbGeAlD
Asenapine—HTR7—female reproductive system—breast cancer	0.000226	0.0131	CbGeAlD
Asenapine—ADRA2C—adipose tissue—breast cancer	0.000226	0.0131	CbGeAlD
Asenapine—SLC6A4—endocrine gland—breast cancer	0.000226	0.0131	CbGeAlD
Asenapine—HTR7—adrenal gland—breast cancer	0.000221	0.0128	CbGeAlD
Asenapine—ADRA1A—adrenal gland—breast cancer	0.000213	0.0123	CbGeAlD
Asenapine—HRH1—endometrium—breast cancer	0.000204	0.0118	CbGeAlD
Asenapine—ADRA2C—adrenal gland—breast cancer	0.000203	0.0117	CbGeAlD
Asenapine—HTR1A—endocrine gland—breast cancer	0.0002	0.0116	CbGeAlD
Asenapine—ADRA2A—endometrium—breast cancer	0.0002	0.0116	CbGeAlD
Asenapine—HTR7—endocrine gland—breast cancer	0.000191	0.0111	CbGeAlD
Asenapine—HTR2A—epithelium—breast cancer	0.00019	0.011	CbGeAlD
Asenapine—ADRA2C—female gonad—breast cancer	0.000189	0.011	CbGeAlD
Asenapine—ADRA1A—endocrine gland—breast cancer	0.000185	0.0107	CbGeAlD
Asenapine—ADRA2A—uterus—breast cancer	0.000185	0.0107	CbGeAlD
Asenapine—HRH1—adipose tissue—breast cancer	0.000184	0.0106	CbGeAlD
Asenapine—ADRA2A—pituitary gland—breast cancer	0.000181	0.0105	CbGeAlD
Asenapine—DRD2—endocrine gland—breast cancer	0.000181	0.0105	CbGeAlD
Asenapine—ADRA2A—adipose tissue—breast cancer	0.00018	0.0105	CbGeAlD
Asenapine—HRH1—female reproductive system—breast cancer	0.000169	0.00978	CbGeAlD
Asenapine—ADRA2A—female reproductive system—breast cancer	0.000166	0.00961	CbGeAlD
Asenapine—HRH1—adrenal gland—breast cancer	0.000165	0.00954	CbGeAlD
Asenapine—ADRA2A—adrenal gland—breast cancer	0.000162	0.00937	CbGeAlD
Asenapine—HTR2B—lymph node—breast cancer	0.000154	0.00895	CbGeAlD
Asenapine—HTR2A—pituitary gland—breast cancer	0.000154	0.00892	CbGeAlD
Asenapine—HRH1—female gonad—breast cancer	0.000154	0.0089	CbGeAlD
Asenapine—CYP1A2—endocrine gland—breast cancer	0.000153	0.00884	CbGeAlD
Asenapine—ADRA2A—female gonad—breast cancer	0.000151	0.00874	CbGeAlD
Asenapine—HRH1—endocrine gland—breast cancer	0.000143	0.00828	CbGeAlD
Asenapine—HTR2A—female reproductive system—breast cancer	0.000141	0.00817	CbGeAlD
Asenapine—ADRA2A—endocrine gland—breast cancer	0.00014	0.00813	CbGeAlD
Asenapine—HTR2A—adrenal gland—breast cancer	0.000138	0.00797	CbGeAlD
Asenapine—CYP3A4—female reproductive system—breast cancer	0.000131	0.00756	CbGeAlD
Asenapine—CYP2D6—female reproductive system—breast cancer	0.000128	0.00744	CbGeAlD
Asenapine—ADRA2C—lymph node—breast cancer	0.000122	0.00704	CbGeAlD
Asenapine—HTR2A—endocrine gland—breast cancer	0.000119	0.00691	CbGeAlD
Asenapine—CYP2D6—female gonad—breast cancer	0.000117	0.00677	CbGeAlD
Asenapine—CYP3A4—endocrine gland—breast cancer	0.00011	0.0064	CbGeAlD
Asenapine—CYP2D6—endocrine gland—breast cancer	0.000109	0.0063	CbGeAlD
Asenapine—HRH1—lymph node—breast cancer	9.88e-05	0.00572	CbGeAlD
Asenapine—ADRA2A—lymph node—breast cancer	9.7e-05	0.00562	CbGeAlD
Asenapine—Tremor—Capecitabine—breast cancer	7.37e-05	0.000377	CcSEcCtD
Asenapine—Neutropenia—Epirubicin—breast cancer	7.35e-05	0.000377	CcSEcCtD
Asenapine—Dizziness—Thiotepa—breast cancer	7.34e-05	0.000376	CcSEcCtD
Asenapine—Rash—Vinorelbine—breast cancer	7.33e-05	0.000375	CcSEcCtD
Asenapine—Dermatitis—Vinorelbine—breast cancer	7.33e-05	0.000375	CcSEcCtD
Asenapine—Hypotension—Paclitaxel—breast cancer	7.31e-05	0.000374	CcSEcCtD
Asenapine—Stomatitis—Methotrexate—breast cancer	7.3e-05	0.000374	CcSEcCtD
Asenapine—Headache—Vinorelbine—breast cancer	7.29e-05	0.000373	CcSEcCtD
Asenapine—Syncope—Docetaxel—breast cancer	7.29e-05	0.000373	CcSEcCtD
Asenapine—Dysphagia—Doxorubicin—breast cancer	7.28e-05	0.000373	CcSEcCtD
Asenapine—Leukopenia—Docetaxel—breast cancer	7.27e-05	0.000372	CcSEcCtD
Asenapine—Anaemia—Capecitabine—breast cancer	7.27e-05	0.000372	CcSEcCtD
Asenapine—Weight increased—Epirubicin—breast cancer	7.16e-05	0.000366	CcSEcCtD
Asenapine—Loss of consciousness—Docetaxel—breast cancer	7.14e-05	0.000366	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Paclitaxel—breast cancer	7.13e-05	0.000365	CcSEcCtD
Asenapine—Hyperglycaemia—Epirubicin—breast cancer	7.09e-05	0.000363	CcSEcCtD
Asenapine—Malaise—Capecitabine—breast cancer	7.09e-05	0.000363	CcSEcCtD
Asenapine—Hepatobiliary disease—Methotrexate—breast cancer	7.09e-05	0.000363	CcSEcCtD
Asenapine—Insomnia—Paclitaxel—breast cancer	7.08e-05	0.000362	CcSEcCtD
Asenapine—Hypersensitivity—Mitoxantrone—breast cancer	7.07e-05	0.000362	CcSEcCtD
Asenapine—Hypersensitivity—Irinotecan—breast cancer	7.07e-05	0.000362	CcSEcCtD
Asenapine—Vomiting—Thiotepa—breast cancer	7.06e-05	0.000362	CcSEcCtD
Asenapine—Syncope—Capecitabine—breast cancer	7.05e-05	0.000361	CcSEcCtD
Asenapine—Leukopenia—Capecitabine—breast cancer	7.04e-05	0.000361	CcSEcCtD
Asenapine—Convulsion—Docetaxel—breast cancer	7.04e-05	0.00036	CcSEcCtD
Asenapine—Hypertension—Docetaxel—breast cancer	7.01e-05	0.000359	CcSEcCtD
Asenapine—Rash—Thiotepa—breast cancer	7e-05	0.000359	CcSEcCtD
Asenapine—Dermatitis—Thiotepa—breast cancer	7e-05	0.000358	CcSEcCtD
Asenapine—Agranulocytosis—Methotrexate—breast cancer	6.99e-05	0.000358	CcSEcCtD
Asenapine—Dyspnoea—Paclitaxel—breast cancer	6.97e-05	0.000357	CcSEcCtD
Asenapine—Headache—Thiotepa—breast cancer	6.96e-05	0.000356	CcSEcCtD
Asenapine—Somnolence—Paclitaxel—breast cancer	6.95e-05	0.000356	CcSEcCtD
Asenapine—Arthralgia—Docetaxel—breast cancer	6.92e-05	0.000354	CcSEcCtD
Asenapine—Loss of consciousness—Capecitabine—breast cancer	6.91e-05	0.000354	CcSEcCtD
Asenapine—Nausea—Vinorelbine—breast cancer	6.91e-05	0.000354	CcSEcCtD
Asenapine—Dyspepsia—Paclitaxel—breast cancer	6.89e-05	0.000353	CcSEcCtD
Asenapine—Asthenia—Mitoxantrone—breast cancer	6.88e-05	0.000352	CcSEcCtD
Asenapine—Asthenia—Irinotecan—breast cancer	6.88e-05	0.000352	CcSEcCtD
Asenapine—Stomatitis—Epirubicin—breast cancer	6.83e-05	0.00035	CcSEcCtD
Asenapine—Neutropenia—Doxorubicin—breast cancer	6.8e-05	0.000348	CcSEcCtD
Asenapine—Hypertension—Capecitabine—breast cancer	6.79e-05	0.000348	CcSEcCtD
Asenapine—Hypersensitivity—Fluorouracil—breast cancer	6.77e-05	0.000347	CcSEcCtD
Asenapine—Dry mouth—Docetaxel—breast cancer	6.76e-05	0.000346	CcSEcCtD
Asenapine—Gastrointestinal disorder—Paclitaxel—breast cancer	6.75e-05	0.000346	CcSEcCtD
Asenapine—Fatigue—Paclitaxel—breast cancer	6.74e-05	0.000345	CcSEcCtD
Asenapine—Asthenia—Gemcitabine—breast cancer	6.7e-05	0.000343	CcSEcCtD
Asenapine—Arthralgia—Capecitabine—breast cancer	6.7e-05	0.000343	CcSEcCtD
Asenapine—Constipation—Paclitaxel—breast cancer	6.69e-05	0.000343	CcSEcCtD
Asenapine—Anxiety—Capecitabine—breast cancer	6.67e-05	0.000342	CcSEcCtD
Asenapine—Hepatobiliary disease—Epirubicin—breast cancer	6.63e-05	0.00034	CcSEcCtD
Asenapine—Anaphylactic shock—Docetaxel—breast cancer	6.63e-05	0.00034	CcSEcCtD
Asenapine—Weight increased—Doxorubicin—breast cancer	6.62e-05	0.000339	CcSEcCtD
Asenapine—Nausea—Thiotepa—breast cancer	6.6e-05	0.000338	CcSEcCtD
Asenapine—Hyperglycaemia—Doxorubicin—breast cancer	6.56e-05	0.000336	CcSEcCtD
Asenapine—Dry mouth—Capecitabine—breast cancer	6.55e-05	0.000335	CcSEcCtD
Asenapine—Agranulocytosis—Epirubicin—breast cancer	6.54e-05	0.000335	CcSEcCtD
Asenapine—Shock—Docetaxel—breast cancer	6.52e-05	0.000334	CcSEcCtD
Asenapine—Nervous system disorder—Docetaxel—breast cancer	6.5e-05	0.000333	CcSEcCtD
Asenapine—Thrombocytopenia—Docetaxel—breast cancer	6.49e-05	0.000332	CcSEcCtD
Asenapine—Tachycardia—Docetaxel—breast cancer	6.47e-05	0.000331	CcSEcCtD
Asenapine—Dizziness—Irinotecan—breast cancer	6.34e-05	0.000325	CcSEcCtD
Asenapine—Stomatitis—Doxorubicin—breast cancer	6.32e-05	0.000324	CcSEcCtD
Asenapine—Shock—Capecitabine—breast cancer	6.32e-05	0.000323	CcSEcCtD
Asenapine—Nervous system disorder—Capecitabine—breast cancer	6.3e-05	0.000322	CcSEcCtD
Asenapine—Eye disorder—Methotrexate—breast cancer	6.29e-05	0.000322	CcSEcCtD
Asenapine—Thrombocytopenia—Capecitabine—breast cancer	6.29e-05	0.000322	CcSEcCtD
Asenapine—Tachycardia—Capecitabine—breast cancer	6.27e-05	0.000321	CcSEcCtD
Asenapine—Cardiac disorder—Methotrexate—breast cancer	6.24e-05	0.00032	CcSEcCtD
Asenapine—Oedema peripheral—Epirubicin—breast cancer	6.2e-05	0.000318	CcSEcCtD
Asenapine—Hypotension—Docetaxel—breast cancer	6.2e-05	0.000317	CcSEcCtD
Asenapine—Connective tissue disorder—Epirubicin—breast cancer	6.19e-05	0.000317	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—breast cancer	6.14e-05	0.000314	CcSEcCtD
Asenapine—Angiopathy—Methotrexate—breast cancer	6.1e-05	0.000312	CcSEcCtD
Asenapine—Vomiting—Irinotecan—breast cancer	6.1e-05	0.000312	CcSEcCtD
Asenapine—Vomiting—Mitoxantrone—breast cancer	6.1e-05	0.000312	CcSEcCtD
Asenapine—Immune system disorder—Methotrexate—breast cancer	6.08e-05	0.000311	CcSEcCtD
Asenapine—Dizziness—Fluorouracil—breast cancer	6.07e-05	0.000311	CcSEcCtD
Asenapine—Mediastinal disorder—Methotrexate—breast cancer	6.06e-05	0.00031	CcSEcCtD
Asenapine—Agranulocytosis—Doxorubicin—breast cancer	6.05e-05	0.00031	CcSEcCtD
Asenapine—Rash—Irinotecan—breast cancer	6.05e-05	0.00031	CcSEcCtD
Asenapine—Rash—Mitoxantrone—breast cancer	6.05e-05	0.00031	CcSEcCtD
Asenapine—Dermatitis—Mitoxantrone—breast cancer	6.04e-05	0.000309	CcSEcCtD
Asenapine—Dermatitis—Irinotecan—breast cancer	6.04e-05	0.000309	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Docetaxel—breast cancer	6.04e-05	0.000309	CcSEcCtD
Asenapine—Headache—Mitoxantrone—breast cancer	6.01e-05	0.000308	CcSEcCtD
Asenapine—Headache—Irinotecan—breast cancer	6.01e-05	0.000308	CcSEcCtD
Asenapine—Hypotension—Capecitabine—breast cancer	6e-05	0.000307	CcSEcCtD
Asenapine—Insomnia—Docetaxel—breast cancer	6e-05	0.000307	CcSEcCtD
Asenapine—Vomiting—Gemcitabine—breast cancer	5.94e-05	0.000304	CcSEcCtD
Asenapine—Dyspnoea—Docetaxel—breast cancer	5.91e-05	0.000303	CcSEcCtD
Asenapine—Somnolence—Docetaxel—breast cancer	5.89e-05	0.000302	CcSEcCtD
Asenapine—Mental disorder—Methotrexate—breast cancer	5.89e-05	0.000302	CcSEcCtD
Asenapine—Rash—Gemcitabine—breast cancer	5.89e-05	0.000302	CcSEcCtD
Asenapine—Dermatitis—Gemcitabine—breast cancer	5.89e-05	0.000301	CcSEcCtD
Asenapine—Eye disorder—Epirubicin—breast cancer	5.88e-05	0.000301	CcSEcCtD
Asenapine—Malnutrition—Methotrexate—breast cancer	5.86e-05	0.0003	CcSEcCtD
Asenapine—Headache—Gemcitabine—breast cancer	5.85e-05	0.0003	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Capecitabine—breast cancer	5.85e-05	0.000299	CcSEcCtD
Asenapine—Cardiac disorder—Epirubicin—breast cancer	5.84e-05	0.000299	CcSEcCtD
Asenapine—Vomiting—Fluorouracil—breast cancer	5.84e-05	0.000299	CcSEcCtD
Asenapine—Dyspepsia—Docetaxel—breast cancer	5.84e-05	0.000299	CcSEcCtD
Asenapine—Insomnia—Capecitabine—breast cancer	5.81e-05	0.000297	CcSEcCtD
Asenapine—Rash—Fluorouracil—breast cancer	5.79e-05	0.000297	CcSEcCtD
Asenapine—Dermatitis—Fluorouracil—breast cancer	5.79e-05	0.000296	CcSEcCtD
Asenapine—Hypersensitivity—Paclitaxel—breast cancer	5.76e-05	0.000295	CcSEcCtD
Asenapine—Headache—Fluorouracil—breast cancer	5.75e-05	0.000295	CcSEcCtD
Asenapine—Oedema peripheral—Doxorubicin—breast cancer	5.74e-05	0.000294	CcSEcCtD
Asenapine—Dysgeusia—Methotrexate—breast cancer	5.73e-05	0.000294	CcSEcCtD
Asenapine—Gastrointestinal disorder—Docetaxel—breast cancer	5.72e-05	0.000293	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—breast cancer	5.72e-05	0.000293	CcSEcCtD
Asenapine—Dyspnoea—Capecitabine—breast cancer	5.72e-05	0.000293	CcSEcCtD
Asenapine—Fatigue—Docetaxel—breast cancer	5.72e-05	0.000293	CcSEcCtD
Asenapine—Angiopathy—Epirubicin—breast cancer	5.71e-05	0.000292	CcSEcCtD
Asenapine—Nausea—Irinotecan—breast cancer	5.7e-05	0.000292	CcSEcCtD
Asenapine—Nausea—Mitoxantrone—breast cancer	5.7e-05	0.000292	CcSEcCtD
Asenapine—Immune system disorder—Epirubicin—breast cancer	5.69e-05	0.000291	CcSEcCtD
Asenapine—Mediastinal disorder—Epirubicin—breast cancer	5.67e-05	0.000291	CcSEcCtD
Asenapine—Constipation—Docetaxel—breast cancer	5.67e-05	0.00029	CcSEcCtD
Asenapine—Dyspepsia—Capecitabine—breast cancer	5.65e-05	0.000289	CcSEcCtD
Asenapine—Asthenia—Paclitaxel—breast cancer	5.61e-05	0.000287	CcSEcCtD
Asenapine—Nausea—Gemcitabine—breast cancer	5.55e-05	0.000284	CcSEcCtD
Asenapine—Gastrointestinal disorder—Capecitabine—breast cancer	5.54e-05	0.000284	CcSEcCtD
Asenapine—Fatigue—Capecitabine—breast cancer	5.53e-05	0.000283	CcSEcCtD
Asenapine—Mental disorder—Epirubicin—breast cancer	5.51e-05	0.000282	CcSEcCtD
Asenapine—Constipation—Capecitabine—breast cancer	5.49e-05	0.000281	CcSEcCtD
Asenapine—Malnutrition—Epirubicin—breast cancer	5.48e-05	0.000281	CcSEcCtD
Asenapine—Nausea—Fluorouracil—breast cancer	5.46e-05	0.000279	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—breast cancer	5.44e-05	0.000279	CcSEcCtD
Asenapine—Anaemia—Methotrexate—breast cancer	5.41e-05	0.000277	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—breast cancer	5.41e-05	0.000277	CcSEcCtD
Asenapine—Dysgeusia—Epirubicin—breast cancer	5.37e-05	0.000275	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—breast cancer	5.28e-05	0.000271	CcSEcCtD
Asenapine—Malaise—Methotrexate—breast cancer	5.28e-05	0.00027	CcSEcCtD
Asenapine—Muscle spasms—Epirubicin—breast cancer	5.27e-05	0.00027	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—breast cancer	5.26e-05	0.000269	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—breast cancer	5.25e-05	0.000269	CcSEcCtD
Asenapine—Leukopenia—Methotrexate—breast cancer	5.24e-05	0.000268	CcSEcCtD
Asenapine—Dizziness—Paclitaxel—breast cancer	5.17e-05	0.000265	CcSEcCtD
Asenapine—Mental disorder—Doxorubicin—breast cancer	5.1e-05	0.000261	CcSEcCtD
Asenapine—Convulsion—Methotrexate—breast cancer	5.07e-05	0.00026	CcSEcCtD
Asenapine—Malnutrition—Doxorubicin—breast cancer	5.07e-05	0.00026	CcSEcCtD
Asenapine—Anaemia—Epirubicin—breast cancer	5.06e-05	0.000259	CcSEcCtD
Asenapine—Agitation—Epirubicin—breast cancer	5.04e-05	0.000258	CcSEcCtD
Asenapine—Arthralgia—Methotrexate—breast cancer	4.99e-05	0.000255	CcSEcCtD
Asenapine—Vomiting—Paclitaxel—breast cancer	4.97e-05	0.000255	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—breast cancer	4.97e-05	0.000254	CcSEcCtD
Asenapine—Malaise—Epirubicin—breast cancer	4.94e-05	0.000253	CcSEcCtD
Asenapine—Rash—Paclitaxel—breast cancer	4.93e-05	0.000253	CcSEcCtD
Asenapine—Dermatitis—Paclitaxel—breast cancer	4.93e-05	0.000252	CcSEcCtD
Asenapine—Syncope—Epirubicin—breast cancer	4.91e-05	0.000252	CcSEcCtD
Asenapine—Leukopenia—Epirubicin—breast cancer	4.9e-05	0.000251	CcSEcCtD
Asenapine—Headache—Paclitaxel—breast cancer	4.9e-05	0.000251	CcSEcCtD
Asenapine—Hypersensitivity—Docetaxel—breast cancer	4.89e-05	0.00025	CcSEcCtD
Asenapine—Muscle spasms—Doxorubicin—breast cancer	4.87e-05	0.00025	CcSEcCtD
Asenapine—Loss of consciousness—Epirubicin—breast cancer	4.82e-05	0.000247	CcSEcCtD
Asenapine—Anaphylactic shock—Methotrexate—breast cancer	4.78e-05	0.000245	CcSEcCtD
Asenapine—Asthenia—Docetaxel—breast cancer	4.76e-05	0.000244	CcSEcCtD
Asenapine—Convulsion—Epirubicin—breast cancer	4.75e-05	0.000243	CcSEcCtD
Asenapine—Hypertension—Epirubicin—breast cancer	4.73e-05	0.000242	CcSEcCtD
Asenapine—Hypersensitivity—Capecitabine—breast cancer	4.73e-05	0.000242	CcSEcCtD
Asenapine—Nervous system disorder—Methotrexate—breast cancer	4.69e-05	0.00024	CcSEcCtD
Asenapine—Anaemia—Doxorubicin—breast cancer	4.69e-05	0.00024	CcSEcCtD
Asenapine—Thrombocytopenia—Methotrexate—breast cancer	4.68e-05	0.00024	CcSEcCtD
Asenapine—Arthralgia—Epirubicin—breast cancer	4.67e-05	0.000239	CcSEcCtD
Asenapine—Agitation—Doxorubicin—breast cancer	4.66e-05	0.000239	CcSEcCtD
Asenapine—Anxiety—Epirubicin—breast cancer	4.65e-05	0.000238	CcSEcCtD
Asenapine—Nausea—Paclitaxel—breast cancer	4.65e-05	0.000238	CcSEcCtD
Asenapine—Asthenia—Capecitabine—breast cancer	4.61e-05	0.000236	CcSEcCtD
Asenapine—Malaise—Doxorubicin—breast cancer	4.57e-05	0.000234	CcSEcCtD
Asenapine—Dry mouth—Epirubicin—breast cancer	4.56e-05	0.000234	CcSEcCtD
Asenapine—Syncope—Doxorubicin—breast cancer	4.55e-05	0.000233	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—breast cancer	4.54e-05	0.000232	CcSEcCtD
Asenapine—Anaphylactic shock—Epirubicin—breast cancer	4.47e-05	0.000229	CcSEcCtD
Asenapine—Hypotension—Methotrexate—breast cancer	4.47e-05	0.000229	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—breast cancer	4.46e-05	0.000228	CcSEcCtD
Asenapine—Shock—Epirubicin—breast cancer	4.4e-05	0.000225	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—breast cancer	4.39e-05	0.000225	CcSEcCtD
Asenapine—Nervous system disorder—Epirubicin—breast cancer	4.39e-05	0.000225	CcSEcCtD
Asenapine—Dizziness—Docetaxel—breast cancer	4.38e-05	0.000225	CcSEcCtD
Asenapine—Thrombocytopenia—Epirubicin—breast cancer	4.38e-05	0.000224	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—breast cancer	4.38e-05	0.000224	CcSEcCtD
Asenapine—Tachycardia—Epirubicin—breast cancer	4.36e-05	0.000224	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Methotrexate—breast cancer	4.35e-05	0.000223	CcSEcCtD
Asenapine—Insomnia—Methotrexate—breast cancer	4.32e-05	0.000221	CcSEcCtD
Asenapine—Arthralgia—Doxorubicin—breast cancer	4.32e-05	0.000221	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—breast cancer	4.3e-05	0.00022	CcSEcCtD
Asenapine—Dyspnoea—Methotrexate—breast cancer	4.26e-05	0.000218	CcSEcCtD
Asenapine—Somnolence—Methotrexate—breast cancer	4.25e-05	0.000218	CcSEcCtD
Asenapine—Dizziness—Capecitabine—breast cancer	4.25e-05	0.000217	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—breast cancer	4.22e-05	0.000216	CcSEcCtD
Asenapine—Vomiting—Docetaxel—breast cancer	4.22e-05	0.000216	CcSEcCtD
Asenapine—Dyspepsia—Methotrexate—breast cancer	4.21e-05	0.000215	CcSEcCtD
Asenapine—Rash—Docetaxel—breast cancer	4.18e-05	0.000214	CcSEcCtD
Asenapine—Hypotension—Epirubicin—breast cancer	4.18e-05	0.000214	CcSEcCtD
Asenapine—Dermatitis—Docetaxel—breast cancer	4.18e-05	0.000214	CcSEcCtD
Asenapine—Headache—Docetaxel—breast cancer	4.15e-05	0.000213	CcSEcCtD
Asenapine—Anaphylactic shock—Doxorubicin—breast cancer	4.14e-05	0.000212	CcSEcCtD
Asenapine—Gastrointestinal disorder—Methotrexate—breast cancer	4.13e-05	0.000211	CcSEcCtD
Asenapine—Fatigue—Methotrexate—breast cancer	4.12e-05	0.000211	CcSEcCtD
Asenapine—Vomiting—Capecitabine—breast cancer	4.08e-05	0.000209	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Epirubicin—breast cancer	4.07e-05	0.000209	CcSEcCtD
Asenapine—Shock—Doxorubicin—breast cancer	4.07e-05	0.000208	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—breast cancer	4.06e-05	0.000208	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—breast cancer	4.05e-05	0.000207	CcSEcCtD
Asenapine—Rash—Capecitabine—breast cancer	4.05e-05	0.000207	CcSEcCtD
Asenapine—Insomnia—Epirubicin—breast cancer	4.04e-05	0.000207	CcSEcCtD
Asenapine—Dermatitis—Capecitabine—breast cancer	4.04e-05	0.000207	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—breast cancer	4.04e-05	0.000207	CcSEcCtD
Asenapine—Headache—Capecitabine—breast cancer	4.02e-05	0.000206	CcSEcCtD
Asenapine—Dyspnoea—Epirubicin—breast cancer	3.99e-05	0.000204	CcSEcCtD
Asenapine—Somnolence—Epirubicin—breast cancer	3.98e-05	0.000204	CcSEcCtD
Asenapine—Nausea—Docetaxel—breast cancer	3.94e-05	0.000202	CcSEcCtD
Asenapine—Dyspepsia—Epirubicin—breast cancer	3.94e-05	0.000202	CcSEcCtD
Asenapine—Hypotension—Doxorubicin—breast cancer	3.87e-05	0.000198	CcSEcCtD
Asenapine—Gastrointestinal disorder—Epirubicin—breast cancer	3.86e-05	0.000198	CcSEcCtD
Asenapine—Fatigue—Epirubicin—breast cancer	3.86e-05	0.000197	CcSEcCtD
Asenapine—Constipation—Epirubicin—breast cancer	3.82e-05	0.000196	CcSEcCtD
Asenapine—Nausea—Capecitabine—breast cancer	3.81e-05	0.000195	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.77e-05	0.000193	CcSEcCtD
Asenapine—Insomnia—Doxorubicin—breast cancer	3.74e-05	0.000192	CcSEcCtD
Asenapine—Dyspnoea—Doxorubicin—breast cancer	3.69e-05	0.000189	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—breast cancer	3.68e-05	0.000188	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—breast cancer	3.64e-05	0.000187	CcSEcCtD
Asenapine—Gastrointestinal disorder—Doxorubicin—breast cancer	3.57e-05	0.000183	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—breast cancer	3.57e-05	0.000183	CcSEcCtD
Asenapine—Constipation—Doxorubicin—breast cancer	3.54e-05	0.000181	CcSEcCtD
Asenapine—Hypersensitivity—Methotrexate—breast cancer	3.52e-05	0.00018	CcSEcCtD
Asenapine—Asthenia—Methotrexate—breast cancer	3.43e-05	0.000176	CcSEcCtD
Asenapine—Hypersensitivity—Epirubicin—breast cancer	3.29e-05	0.000169	CcSEcCtD
Asenapine—Asthenia—Epirubicin—breast cancer	3.21e-05	0.000164	CcSEcCtD
Asenapine—Dizziness—Methotrexate—breast cancer	3.16e-05	0.000162	CcSEcCtD
Asenapine—Hypersensitivity—Doxorubicin—breast cancer	3.05e-05	0.000156	CcSEcCtD
Asenapine—Vomiting—Methotrexate—breast cancer	3.04e-05	0.000156	CcSEcCtD
Asenapine—Rash—Methotrexate—breast cancer	3.01e-05	0.000154	CcSEcCtD
Asenapine—Dermatitis—Methotrexate—breast cancer	3.01e-05	0.000154	CcSEcCtD
Asenapine—Headache—Methotrexate—breast cancer	2.99e-05	0.000153	CcSEcCtD
Asenapine—Asthenia—Doxorubicin—breast cancer	2.97e-05	0.000152	CcSEcCtD
Asenapine—Dizziness—Epirubicin—breast cancer	2.96e-05	0.000151	CcSEcCtD
Asenapine—Vomiting—Epirubicin—breast cancer	2.84e-05	0.000146	CcSEcCtD
Asenapine—Nausea—Methotrexate—breast cancer	2.84e-05	0.000145	CcSEcCtD
Asenapine—Rash—Epirubicin—breast cancer	2.82e-05	0.000144	CcSEcCtD
Asenapine—Dermatitis—Epirubicin—breast cancer	2.82e-05	0.000144	CcSEcCtD
Asenapine—Headache—Epirubicin—breast cancer	2.8e-05	0.000143	CcSEcCtD
Asenapine—Dizziness—Doxorubicin—breast cancer	2.74e-05	0.00014	CcSEcCtD
Asenapine—Nausea—Epirubicin—breast cancer	2.66e-05	0.000136	CcSEcCtD
Asenapine—Vomiting—Doxorubicin—breast cancer	2.63e-05	0.000135	CcSEcCtD
Asenapine—Rash—Doxorubicin—breast cancer	2.61e-05	0.000134	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—breast cancer	2.61e-05	0.000133	CcSEcCtD
Asenapine—Headache—Doxorubicin—breast cancer	2.59e-05	0.000133	CcSEcCtD
Asenapine—Nausea—Doxorubicin—breast cancer	2.46e-05	0.000126	CcSEcCtD
Asenapine—ADRB1—Signaling Pathways—MAPK3—breast cancer	1.44e-06	1.06e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—JUN—breast cancer	1.44e-06	1.06e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—breast cancer	1.44e-06	1.06e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—breast cancer	1.44e-06	1.06e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—JUN—breast cancer	1.44e-06	1.06e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—COMT—breast cancer	1.44e-06	1.05e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—STAT3—breast cancer	1.43e-06	1.05e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CTNNB1—breast cancer	1.43e-06	1.05e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTP1—breast cancer	1.43e-06	1.05e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MAPK3—breast cancer	1.43e-06	1.05e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CTNNB1—breast cancer	1.43e-06	1.05e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MMP9—breast cancer	1.42e-06	1.05e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—breast cancer	1.42e-06	1.04e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—breast cancer	1.42e-06	1.04e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—breast cancer	1.42e-06	1.04e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—breast cancer	1.42e-06	1.04e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CDKN1A—breast cancer	1.42e-06	1.04e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—breast cancer	1.42e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—breast cancer	1.41e-06	1.04e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—breast cancer	1.41e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—JUN—breast cancer	1.41e-06	1.04e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—HMOX1—breast cancer	1.41e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CXCL8—breast cancer	1.41e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—VEGFA—breast cancer	1.41e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MAPK3—breast cancer	1.41e-06	1.04e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ITPR1—breast cancer	1.41e-06	1.03e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PIK3CA—breast cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MMP9—breast cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MYC—breast cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MMP9—breast cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TGFB1—breast cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CDKN1A—breast cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—STAT3—breast cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CDKN1A—breast cancer	1.39e-06	1.02e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—breast cancer	1.39e-06	1.02e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—breast cancer	1.39e-06	1.02e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MYC—breast cancer	1.39e-06	1.02e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—CAV1—breast cancer	1.39e-06	1.02e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK8—breast cancer	1.38e-06	1.02e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TGFB1—breast cancer	1.38e-06	1.02e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—breast cancer	1.38e-06	1.01e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—AKT1—breast cancer	1.38e-06	1.01e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MAPK3—breast cancer	1.38e-06	1.01e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	1.38e-06	1.01e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MMP9—breast cancer	1.37e-06	1.01e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MAPK3—breast cancer	1.37e-06	1.01e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MYC—breast cancer	1.37e-06	1.01e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EGFR—breast cancer	1.37e-06	1.01e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	1.37e-06	1e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TGFB1—breast cancer	1.37e-06	1e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—breast cancer	1.36e-06	1e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK8—breast cancer	1.36e-06	1e-05	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	1.36e-06	1e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—IL6—breast cancer	1.36e-06	1e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK8—breast cancer	1.36e-06	9.99e-06	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—breast cancer	1.36e-06	9.99e-06	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—IL6—breast cancer	1.36e-06	9.99e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—AKT1—breast cancer	1.36e-06	9.98e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EGFR—breast cancer	1.36e-06	9.97e-06	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—breast cancer	1.36e-06	9.97e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—AKT1—breast cancer	1.36e-06	9.96e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ABCB1—breast cancer	1.35e-06	9.94e-06	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—IL6—breast cancer	1.35e-06	9.92e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CASP3—breast cancer	1.35e-06	9.91e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL2—breast cancer	1.35e-06	9.89e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EGFR—breast cancer	1.34e-06	9.85e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—IL6—breast cancer	1.34e-06	9.85e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MYC—breast cancer	1.34e-06	9.84e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TGFB1—breast cancer	1.34e-06	9.82e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK8—breast cancer	1.33e-06	9.8e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MAPK3—breast cancer	1.33e-06	9.79e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MYC—breast cancer	1.33e-06	9.79e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—AKT1—breast cancer	1.33e-06	9.78e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TGFB1—breast cancer	1.33e-06	9.77e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—TYMS—breast cancer	1.33e-06	9.76e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.33e-06	9.74e-06	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PIK3CA—breast cancer	1.32e-06	9.72e-06	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—IL6—breast cancer	1.32e-06	9.71e-06	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PIK3CA—breast cancer	1.32e-06	9.67e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTM1—breast cancer	1.31e-06	9.65e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—NCOR1—breast cancer	1.31e-06	9.65e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.31e-06	9.65e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—breast cancer	1.31e-06	9.65e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—SRC—breast cancer	1.31e-06	9.64e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CD—breast cancer	1.31e-06	9.63e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EGFR—breast cancer	1.31e-06	9.63e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—JUN—breast cancer	1.31e-06	9.63e-06	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PIK3CA—breast cancer	1.3e-06	9.59e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EGFR—breast cancer	1.3e-06	9.58e-06	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—IL6—breast cancer	1.3e-06	9.56e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	1.3e-06	9.55e-06	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—breast cancer	1.3e-06	9.53e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MYC—breast cancer	1.3e-06	9.53e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—breast cancer	1.29e-06	9.51e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—ALB—breast cancer	1.29e-06	9.51e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TGFB1—breast cancer	1.29e-06	9.5e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—SRC—breast cancer	1.29e-06	9.49e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—SRC—breast cancer	1.29e-06	9.47e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—breast cancer	1.28e-06	9.42e-06	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—breast cancer	1.28e-06	9.4e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—VEGFA—breast cancer	1.28e-06	9.39e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MMP9—breast cancer	1.27e-06	9.36e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	1.27e-06	9.33e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EGFR—breast cancer	1.27e-06	9.32e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—breast cancer	1.27e-06	9.31e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—breast cancer	1.27e-06	9.3e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—STAT3—breast cancer	1.27e-06	9.3e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—SRC—breast cancer	1.26e-06	9.29e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CG—breast cancer	1.26e-06	9.28e-06	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—breast cancer	1.26e-06	9.28e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—VEGFA—breast cancer	1.26e-06	9.24e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GPX1—breast cancer	1.26e-06	9.24e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—VEGFA—breast cancer	1.26e-06	9.22e-06	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—AKT1—breast cancer	1.26e-06	9.22e-06	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—AKT1—breast cancer	1.25e-06	9.21e-06	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—AKT1—breast cancer	1.25e-06	9.15e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—STAT3—breast cancer	1.25e-06	9.15e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CYP1A1—breast cancer	1.24e-06	9.15e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—STAT3—breast cancer	1.24e-06	9.13e-06	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—IL6—breast cancer	1.24e-06	9.12e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	1.24e-06	9.11e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—NOS3—breast cancer	1.24e-06	9.1e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—breast cancer	1.24e-06	9.1e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	1.24e-06	9.08e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ERCC2—breast cancer	1.23e-06	9.07e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—VEGFA—breast cancer	1.23e-06	9.05e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—breast cancer	1.23e-06	9.05e-06	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—breast cancer	1.22e-06	8.99e-06	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—AKT1—breast cancer	1.22e-06	8.96e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—STAT3—breast cancer	1.22e-06	8.96e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK3—breast cancer	1.21e-06	8.89e-06	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—breast cancer	1.21e-06	8.87e-06	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—AKT1—breast cancer	1.2e-06	8.82e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—breast cancer	1.2e-06	8.8e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK3—breast cancer	1.19e-06	8.74e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PIK3CA—breast cancer	1.19e-06	8.74e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK3—breast cancer	1.19e-06	8.72e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	1.18e-06	8.66e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MYC—breast cancer	1.18e-06	8.64e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—SRC—breast cancer	1.18e-06	8.63e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TGFB1—breast cancer	1.17e-06	8.62e-06	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—IL6—breast cancer	1.17e-06	8.61e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK3—breast cancer	1.17e-06	8.56e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PIK3CA—breast cancer	1.16e-06	8.55e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—MTHFR—breast cancer	1.16e-06	8.53e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MYC—breast cancer	1.16e-06	8.5e-06	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—IL6—breast cancer	1.16e-06	8.49e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MYC—breast cancer	1.15e-06	8.49e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TGFB1—breast cancer	1.15e-06	8.48e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TGFB1—breast cancer	1.15e-06	8.47e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EGFR—breast cancer	1.15e-06	8.45e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—breast cancer	1.15e-06	8.45e-06	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—AKT1—breast cancer	1.15e-06	8.42e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	1.14e-06	8.41e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CB—breast cancer	1.14e-06	8.4e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—breast cancer	1.14e-06	8.37e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PIK3CA—breast cancer	1.14e-06	8.36e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MYC—breast cancer	1.13e-06	8.33e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—STAT3—breast cancer	1.13e-06	8.33e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTGS2—breast cancer	1.13e-06	8.32e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EGFR—breast cancer	1.13e-06	8.32e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PIK3CA—breast cancer	1.13e-06	8.31e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TGFB1—breast cancer	1.13e-06	8.31e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EGFR—breast cancer	1.13e-06	8.3e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—breast cancer	1.13e-06	8.27e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CD—breast cancer	1.11e-06	8.16e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EGFR—breast cancer	1.11e-06	8.14e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	1.1e-06	8.09e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—breast cancer	1.1e-06	8.08e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—breast cancer	1.1e-06	8.08e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—ALB—breast cancer	1.1e-06	8.06e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—breast cancer	1.09e-06	8.04e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—breast cancer	1.09e-06	8.01e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—breast cancer	1.09e-06	7.99e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	1.08e-06	7.95e-06	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—AKT1—breast cancer	1.08e-06	7.94e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—breast cancer	1.08e-06	7.91e-06	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—AKT1—breast cancer	1.08e-06	7.9e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CAV1—breast cancer	1.07e-06	7.86e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—breast cancer	1.07e-06	7.86e-06	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PIK3CA—breast cancer	1.07e-06	7.85e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—breast cancer	1.07e-06	7.84e-06	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—AKT1—breast cancer	1.07e-06	7.83e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—breast cancer	1.06e-06	7.82e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MYC—breast cancer	1.05e-06	7.74e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—IL6—breast cancer	1.05e-06	7.74e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—breast cancer	1.05e-06	7.73e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	1.05e-06	7.72e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—NOS3—breast cancer	1.05e-06	7.71e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—breast cancer	1.05e-06	7.69e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—breast cancer	1.05e-06	7.69e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—IL6—breast cancer	1.04e-06	7.67e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—IL6—breast cancer	1.03e-06	7.57e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EGFR—breast cancer	1.03e-06	7.57e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—breast cancer	1.02e-06	7.48e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—IL6—breast cancer	1.01e-06	7.4e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—IL6—breast cancer	1e-06	7.36e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PIK3CA—breast cancer	9.99e-07	7.34e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—breast cancer	9.87e-07	7.26e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PIK3CA—breast cancer	9.82e-07	7.22e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PIK3CA—breast cancer	9.8e-07	7.2e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CG—breast cancer	9.75e-07	7.16e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—IL6—breast cancer	9.74e-07	7.16e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—breast cancer	9.73e-07	7.15e-06	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—AKT1—breast cancer	9.71e-07	7.14e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CB—breast cancer	9.68e-07	7.11e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—breast cancer	9.66e-07	7.1e-06	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—AKT1—breast cancer	9.62e-07	7.07e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	9.62e-07	7.07e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTGS2—breast cancer	9.59e-07	7.05e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—breast cancer	9.5e-07	6.98e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—AKT1—breast cancer	9.5e-07	6.98e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—breast cancer	9.48e-07	6.97e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—breast cancer	9.31e-07	6.84e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—AKT1—breast cancer	9.29e-07	6.83e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—AKT1—breast cancer	9.24e-07	6.79e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—breast cancer	9.24e-07	6.79e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—breast cancer	9.09e-07	6.68e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—breast cancer	9.07e-07	6.66e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—AKT1—breast cancer	8.99e-07	6.61e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	8.94e-07	6.57e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—breast cancer	8.9e-07	6.54e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—IL6—breast cancer	8.84e-07	6.5e-06	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—AKT1—breast cancer	8.73e-07	6.42e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—IL6—breast cancer	8.7e-07	6.39e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—IL6—breast cancer	8.68e-07	6.38e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—breast cancer	8.65e-07	6.35e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CD—breast cancer	8.57e-07	6.3e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL6—breast cancer	8.52e-07	6.26e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ALB—breast cancer	8.46e-07	6.22e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—breast cancer	8.36e-07	6.15e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—breast cancer	8.27e-07	6.08e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—AKT1—breast cancer	8.16e-07	5.99e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—NOS3—breast cancer	8.09e-07	5.95e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—AKT1—breast cancer	8.03e-07	5.9e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—AKT1—breast cancer	8.01e-07	5.88e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL6—breast cancer	7.91e-07	5.82e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—AKT1—breast cancer	7.86e-07	5.77e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CB—breast cancer	7.47e-07	5.49e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS2—breast cancer	7.4e-07	5.44e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—AKT1—breast cancer	7.3e-07	5.37e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CA—breast cancer	6.97e-07	5.12e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—breast cancer	6.46e-07	4.74e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CA—breast cancer	5.9e-07	4.34e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—AKT1—breast cancer	5.69e-07	4.18e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—AKT1—breast cancer	4.82e-07	3.54e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CA—breast cancer	4.55e-07	3.35e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—AKT1—breast cancer	3.72e-07	2.73e-06	CbGpPWpGaD
